Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Complementary Therapies in Medicine|September 21, 2020
Biochemical and therapeutic effects of Omega-3 fatty acids in sickle cell diseaseAhmed A Daak, Miguel A Lopez-Toledano, Matthew M HeeneyJournal of Neuropathology and Experimental Neurology|August 5, 2004
The G336S variant in the human neurofilament-M gene does not affect its assembly or distribution: importance of the functional analysis of neurofilament variantsRaul Perez-Olle, Miguel A Lopez-Toledano, Ronald K H LiemJournal of Alzheimer'S Disease : JAD|February 19, 2010
Adult neurogenesis: a potential tool for early diagnosis in Alzheimer's disease?Miguel A Lopez-Toledano, Mohammad Ali Faghihi, Nikunj S Patel, et al.International Journal of Alzheimer'S Disease|July 26, 2011
Knockdown of BACE1-AS Nonprotein-Coding Transcript Modulates Beta-Amyloid-Related Hippocampal NeurogenesisFarzaneh Modarresi, Mohammad Ali Faghihi, Nikunj S Patel, et al.Clinical Therapeutics|February 13, 2017
A Novel ω-3 Acid Ethyl Ester Formulation Incorporating Advanced Lipid Technologies<sup>TM</sup> (ALT<sup>®</sup>) Improves Docosahexaenoic Acid and Eicosapentaenoic Acid Bioavailability Compared with Lovaza<sup>®</sup>Miguel A Lopez-Toledano, Thorsteinn Thorsteinsson, Ahmed Daak, et al.Journal of Clinical Lipidology|May 16, 2017
Minimal food effect for eicosapentaenoic acid and docosahexaenoic acid bioavailability from omega-3-acid ethyl esters with an Advanced Lipid Technologies<sup>TM</sup> (ALT<sup>®</sup>)-based formulationMiguel A Lopez-Toledano, Thorsteinn Thorsteinsson, Ahmed A Daak, et al.CNS Drugs|July 8, 2025
Safety, Tolerability, and Pharmacokinetics of NRL-1049, a Rho-Associated Kinase Inhibitor, in Healthy Volunteers: A Phase 1, First-in-Human, Single-Ascending Dose, Randomized, Placebo-Controlled TrialStuart Madden, Issam Awad, Miguel A Lopez-Toledano, et al.Nature Biotechnology|March 27, 2012
Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulationFarzaneh Modarresi, Mohammad Ali Faghihi, Miguel A Lopez-Toledano, et al.Journal of Drug Delivery|July 31, 2019
Advanced Lipid Technologies® (ALT®): A Proven Formulation Platform to Enhance the Bioavailability of Lipophilic CompoundsMiguel A Lopez-Toledano, Vaibhav Saxena, Jason D Legassie, et al.Proceedings of the National Academy of Sciences of the United States of America|February 7, 2009
MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunctionJannet Kocerha, Mohammad Ali Faghihi, Miguel A Lopez-Toledano, et al.Pageof 2